Peptide hydrogel in vitro non-inflammatory potential.

Peptide hydrogel in vitro non-inflammatory potential.
复制标题

DOI:
10.1002/psc.2940
复制
发表时间:
2017-02
期刊:
Journal of peptide science : an official publication of the European Peptide Society
影响因子:
--
通讯作者:
Saiani A
Saiani A
中科院分区:
其他
文献类型:
--
作者:
Markey A;Workman VL;Bruce IA;Woolford TJ;Derby B;Miller AF;Cartmell SH;Saiani A

文献摘要

被引文献

相似文献

近年来,基于肽的水凝胶引起了人们的极大兴趣,因为这些柔软的、高度水合的材料可以被设计来模仿细胞生态位,在生物医学领域具有巨大的潜在应用。它们在体内的潜在用途尤其取决于它们的生物相容性,包括它们引起炎症反应的潜力。在这项工作中,我们通过将小鼠单核细胞封装在其中(3D 培养)并使用细胞因子、IL-β、IL-6 和 TNFα 的产生作为炎症反应的标志物,体外研究了 β 片层形成肽(FEFEFKFK;F:苯丙氨酸,E:谷氨酸;K:赖氨酸)水凝胶的炎症潜力。培养 48 或 72 小时后,我们的测试样品(培养基 + 凝胶 + 细胞)中没有观察到统计上显着的细胞因子释放,这表明我们的水凝胶不会在体外激发促炎反应。这些结果表明这些水凝胶具有潜在的生物相容性,因此具有体内使用的潜力。这项工作还强调了 2D 与 3D 培养时单核细胞行为、增殖和形态变化的差异。 © 2016 The Authors Journal of Peptide Science 由欧洲肽协会和 John Wiley & Sons Ltd 出版。
Peptide‐based hydrogels have attracted significant interest in recent years as these soft, highly hydrated materials can be engineered to mimic the cell niche with significant potential applications in the biomedical field. Their potential use in vivo in particular is dependent on their biocompatibility, including their potential to cause an inflammatory response. In this work, we investigated in vitro the inflammatory potential of a β‐sheet forming peptide (FEFEFKFK; F: phenylalanine, E: glutamic acid; K: lysine) hydrogel by encapsulating murine monocytes within it (3D culture) and using the production of cytokines, IL‐β, IL‐6 and TNFα, as markers of inflammatory response. No statistically significant release of cytokines in our test sample (media + gel + cells) was observed after 48 or 72 h of culture showing that our hydrogels do not incite a pro‐inflammatory response in vitro. These results show the potential biocompatibility of these hydrogels and therefore their potential for in vivo use. The work also highlighted the difference in monocyte behaviour, proliferation and morphology changes when cultured in 2D vs. 3D. © 2016 The Authors Journal of Peptide Science published by European Peptide Society and John Wiley & Sons Ltd.